Focus Taiwan App
Download

Promising pulmonary fibrosis treatment on path to clinical trials

02/26/2021 06:09 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

A research team at Taiwan's National Yang Ming Chiao Tung University (NYCU) has transferred the technology for its experimental stem cell therapy treatment for pulmonary fibrosis to two biotech companies, in a first step toward beginning clinical trials, it announced Friday.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    172.30.142.119